Federal contract award
75N93023F00003
PHASE I STUDY OF THE INFECTIVITY, SAFETY AND IMMUNOGENICITY OF A RECOMBINANT, LIVE-ATTENUATED, BOVINE/HUMAN, PARAINFLUENZA VIRUS TYPE 3 (B/HPIV3) VECTOR VACCINE EXPRESSING THE SPIKE GLYCOPROTEIN OF SARS-COV-2, DELIVERED BY NASAL SPRAY TO HPIV3-SEROPO
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN43 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | 75N93019D00031 |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $100.6K |
| Current contract value | $100.6K |
| Potential contract value / ceiling | $100.6K |
| Start date | Jun 1, 2023 |
| Current end date | Sep 30, 2024 |
| Potential end date | Sep 30, 2024 |
| Latest award activity | Dec 5, 2024 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 5, 2024 | P00001 | $-959.6K | PHASE I STUDY OF THE INFECTIVITY, SAFETY AND IMMUNOGENICITY OF A RECOMBINANT, LIVE-ATTENUATED, BOVINE/HUMAN, PARAINFLUENZA VIRUS TYPE 3 (B/HPIV3) VECTOR VACCINE EXPRESSING THE SPIKE GLYCOPROTEIN OF SARS-COV-2, DELIVERED BY NASAL SPRAY TO HPIV3-SEROPO |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.